Kiendrébéogo, Joël Arthur
Sidibe, Annick Raissa O.
Compaoré, Ghislain Bertrand
Nacanabo, Relwendé
Sory, Orokia
Ouédraogo, Issa
Nawaz, Saira
Schuind, Anne E
Clark, Andrew
Funding for this research was provided by:
PATH, United States (KFW.0888-38-01710369-SUB, KFW.0888-38-01710369-SUB, KFW.0888-38-01710369-SUB, KFW.0888-38-01710369-SUB, KFW.0888-38-01710369-SUB, KFW.0888-38-01710369-SUB)
Article History
Received: 14 June 2023
Accepted: 6 November 2023
First Online: 1 December 2023
Declarations
:
: This study was conducted in accordance with relevant guidelines and regulations, including the Declaration of Helsinki and has received an ethical approval from the Health Research Ethics Committee from Burkina Faso (deliberation N°2021-07-175). All research participants (experts providing advice) gave voluntary and informed consent to participate in the study.
: Not applicable.
: Two co-authors, ASi and IO, were actively involved in the introduction of the HPV vaccine in Burkina Faso. However, this did not influence the results of the study. Rather, it facilitated access to data to conduct the study. The other authors declare that they have no competing interests.